Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

September 15, 2022

Primary Completion Date

August 27, 2024

Study Completion Date

January 9, 2025

Conditions
Esophagogastric Adenocarcinoma
Interventions
DRUG

Pembrolizumab

400 mg Pembrolizumab day 1 Q6W (max. 18 cycles)

DRUG

Olaparib

300 mg Olaparib bid. cont. day 1 to 42 (max. 16 cycles)

DRUG

mFOLFOX-6

Oxaliplatin 85 mg/m² 2h day 1, 15, 29 plus Leucovorin 400 mg/m² 2h day 1, 15, 29 plus 5-FU 400 mg/m² bolus, followed by 2.400 mg/m² 46h day 1, 15, 29; Q6W, 2 cycles

DRUG

CapOX

Oxaliplatin 130 mg/m² 2h day 1,22 plus Capecitabine 1.000 mg/m² bid. day 1-14, 22-35; Q6W, 2 cycles

Trial Locations (1)

Unknown

Universitätsklinikum Heidelberg, Heidelberg

All Listed Sponsors
lead

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

OTHER